君实生物
TopAlliance

ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT

Shanghai Junshi Biosciences Co., Ltd.

Stock code: 688180.SH; 1877.HK

2024

CONTENTS

About This Report

Introduction

This is the Environmental, Social, and Governance (ESG) Report publicly released by Shanghai Junshi Biosciences Co., Ltd. to comprehensively and authentically present its management practices and achievements in the environmental, social, and governance during its operations to shareholders, employees, regulatory bodies, customers, partners, the public and other stakeholders.

Reporting Scope

This report covers Shanghai Junshi Biosciences Co., Ltd. and its subsidiaries. This report is issued on an annual basis for the period from January 1, 2024 to December 31, 2024, with some content or data dated back to previous years or extended to future years.

Appellation Description

In this report, “Junshi Biosciences”, “the Company”, and “we” all refer to Shanghai Junshi Biosciences Co., Ltd. and its subsidiaries.

Data Sources

The data used in this report are all sourced from the Company and documents and reports officially released by the Company. The financial data in this report is expressed in RMB. Any other currencies used will be specifically noted.

Preparation Basis

This report has been prepared in accordance with *Appendix C2 “Environmental, Social and Governance Reporting Code”* to the *Main Board Listing Rules* of the Stock Exchange of Hong Kong Limited, *Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 14 - Sustainability Report (for Trial Implementation), Global Reporting Initiative Sustainability Reporting Standards (GRI Standards),* and 17 Sustainable Development Goals (SDGs) of the United Nations.

Access to this Report

You may access and download the electronic version of this report at the official websites of the Shanghai Stock Exchange (www.sse.com.cn), Hong Kong Stock Exchange (www.hkex.com.hk), and Shanghai Junshi Biosciences Co., Ltd. to obtain more information on the social responsibility of the Company.

Junshi Biosciences at a Glance

About Junshi Biosciences

Established in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company committed to the discovery, development and commercialization of innovative therapies. In December 2018, the Company was listed on the Main Board of the Stock Exchange of Hong Kong Limited, and in July 2020, the Company was listed on the STAR Market of the Shanghai Stock Exchange. With an outstanding capacity for innovative drug discovery, advanced biotechnology research and development, a whole-industry-chain approach with large-scale production technology, and drug combinations with great market potential, Junshi Biosciences has great potential in tumor immunotherapy as well as the treatment of autoimmune diseases, chronic metabolic diseases, neurological diseases and infectious diseases. The self-development and external cooperation of the Company on a global scale is realized based on its early research in the R&D centers in the United States, Suzhou and Shanghai, while the commercialization process of the Company is optimized by its production bases in Wujiang, Suzhou and Lingang, Shanghai. The Company has all-round capabilities in innovative drug discovery and development, clinical research on a global scale, large-scale production capacity to commercialization on the full industry chain, aiming to become an innovative pharmaceutical company based in China and with a global reach.

Vision

To become an innovative pharmaceutical company in China for global, and to benefit human health.

Mission

To provide patients with world-class, trustworthy, and innovative drugs.

Core Values

Quality First, Truth Seeking, Integrity Compliance, Excellence Pursuit

Honors and Awards

2024.1

Annual Outstanding Partner

Shanxi Cancer Hospital

2024.3

List of 2024 Top 100 Shanghai Hardcore Technology Enterprises

Shanghai Municipal Commission of Economy and Informatization, Shanghai Association for the Promotion of Industrial Technology Innovation, Shanghai Research Center for Industrial Safety Monitoring and Early Warning, Shanghai Association for Science and Technology

2024.4

Top Ten Drug Innovation Leaders of the Year ("Zou Jianjun")

Fourth Drug Innovation Jezebel Awards of *Securities Times*

2024.4

Top 10 Drug Innovation Companies of the Year

Fourth Drug Innovation Jezebel Awards of *Securities Times*

2024.5

2024 Top 100 of Shanghai Specialized and Sophisticated Enterprise Brand Value List

Organizing Committee of China Brand Economy (Shanghai) Forum, Shanghai Institute of Corporate Culture and Brand

2024.6

Elite Enterprises for the 30th Anniversary of the Construction of the Pioneering Park for Overseas Chinese Scholars

Working Committee of Pioneering Park for Overseas Chinese Scholars, China Association of Technology Entrepreneurs

2024.7

T20 China New Drug Development Award (i.e., "Toripalimab")

TONACEA

2024.8



2024 Top 100 Enterprises with Comprehensive Competitiveness in Pharmaceutical Industry

Zhongkang Industrial Research Institute

2024.9



Core Competitiveness Benchmarking Enterprises at China International Economic Management Technology Forum during 2024 China International Trade in Services Fair

Organizing Committee of China International Economic Management Technology Forum at China International Trade in Services Fair, the *Economic Observer*, Organizing Committee of Pharmaceutical Innovation Brand Selection, and China Pharmaceutical Innovation and Research Development Association (PhIRDA)

2024.11

Top 100 Chinese Pharmaceutical Innovative Enterprises in 2024

Healthcare Executive

2024.11

2024 First Prize of Shanghai Digital Intelligence Manufacturing Solution Innovation Competition (Engineering)

Shanghai Digital Intelligence "Smart Craftsmen" and "Leading Pioneers" Selection Committee

2024.12

2024 Top Ten Innovative Biotechnology Cases (i.e., "Toripalimab manufactured by Junshi Biosciences were launched on market in China, the United States, and Europe")

National Business Daily, Financial Lancet, PHARMCUBE

2024.12

2024 Excellent Employer Brand

China Business Journal

2024.12

TOP 10 Influential Chinese Pharmaceutical Companies Going Global 2024

Sino-Foreign Communication Think Tank, in collaboration with China Brand Influence Lab and Health Communication Index Research Institute

2024.12

Winner of Yangtze River Delta Intelligent Manufacturing Solution Innovation Competition (Engineering)

Organizing Committee of China Yangtze River Delta Workers' Labor Skill Innovation Competition

.....

ESG Management

Board Statement

Dear Shareholders, Partners, and Colleagues from all Sectors,

The *2024 Environmental, Social and Governance (ESG) Report* is formally released by the Board of Directors on behalf of Shanghai Junshi Biosciences Co., Ltd. This report comprehensively presents the Company's achievements, core values, and future commitments in sustainable development.

Upholding Governance Responsibilities and Strengthening the Foundation for Development

The Company always regards standardized governance as the core of sustainable development. In 2024, we continuously improved the governance framework of the "General Meeting of Shareholders, Board of Directors, Board of Supervisors, and Senior Management", and revised the list of rights and responsibilities dynamically, to ensure that decision-making is scientific and transparent. The Board of Directors held 13 meetings throughout the year. As of the end of the Reporting Period, 36% of the Company's directors were independent directors and 29% of that were female, fully reflecting the diversity and inclusiveness of governance. The corporate governance of the Company strictly complied with the requirements of the *Company Law of the People's Republic of China* (the "Company Law"), the *Securities Law of the People's Republic of China* (the "Securities Law"), the *Rules Governing the Listing of Stocks on the STAR Market of Shanghai Stock Exchange* (the "SSE STAR Market Listing Rules"), the *Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited* (the "HKEX Market Listing Rules"), other applicable laws, regulations, normative documents, as well as the *Articles of Association of Shanghai Junshi Biosciences Co., Ltd.* (the "*Articles of Association*"). We have been awarded the "Golden Information Disclosure Award" by China Securities Journal, and received the highest Grade A in the "Evaluation of Information Disclosure Work of Listed Companies in SSE for 2023-2024". Additionally, the Company comprehensively controls risks through the C-SOX (Basic Standard for Enterprise Internal Control) internal control system to ensure operational compliance and efficiency.

As for business ethics, we practice anti-corruption, anti-money laundering and anti-monopoly requirements with a "zero tolerance" attitude. In the future, we will further strengthen the construction of a compliance culture and solidify the foundation of corporate integrity.

Sticking to Innovation-driven Development and Safeguarding Life and Health

Innovation is the core competitiveness of Junshi Biosciences. In 2024, the Company invested RMB 1.275 billion in R&D, and obtained 32 additional patents, bringing the total number of patents to 175. Toripalimab is the first anti PD-1 monoclonal antibody independently developed and manufactured in China that was approved for marketing by the FDA, and as the end of the Reporting Period, toripalimab has been approved for marketing in Chinese mainland, Hong Kong SAR of China, the United States, the EU, India, the U.K., Jordan, and other countries and regions, and benefited over one million tumor patients.

The Company, in strict compliance with the ethics of science and technology, establishes a full-process quality management system, which achieves a 0% recall ratio throughout the year and covers 100% of its employees with pharmacovigilance training. We will continue to focus our efforts on patients and promoting more innovative drugs to the world in the future.



Practicing Green Operations and Responding to Climate Change

Environmental responsibility is a key pillar of Junshi Biosciences's sustainable development. In 2024, the Company invested a total of RMB 4.2355 million in environmental protection, the total GHG emissions (Scope 1 + Scope 2) amounting to 26,800.75 tCO_2e. Through the implementation of projects such as steam condensate reuse, we have significantly reduced our energy intensity. In 2025, we plan to further explore the feasibility of using clean energy.

For waste management, we strictly classified and handled 169.31 tons of dangerous waste and entrusted professional organizations to dispose them in a compliant manner, and no environmental violations occurred throughout the year. In the future, we will continue to respond to the “carbon peaking and carbon neutrality” goal, set a scientific path to reduce emissions, and promote the transformation of green production.

Caring for the Growth of Employees and Contributing to the Well-Being of Society

Employees are the most valuable asset of the Company. In 2024, we provided health checkups and vocational training for all employees, achieved 100% of work safety training coverage, and increased the percentage of female employees to 52.4%. Through equity incentive plans and diverse promotion channels, we help our employees realize their professional value, and our employee turnover rate was lower than the industry average level for the year.

In the field of social responsibility, the Company support the construction of primary-level medical emergency systems through donation and conducted a lung cancer public consultation event that benefited tumor patients. Committed to our mission of “Benefiting patients with innovative drugs”, we have been promoting the inclusion of the Company's product into the National Reimbursement Drug List (NRDL) to reduce the financial burden on patients. In the future, we will deepen the rural revitalization, medical assistance and other public welfare actions to practice corporate responsibility.

We understand that sustainable development is a long-term mission. The Board of Directors will always work hand in hand with shareholders, employees, customers and communities to move towards a healthy, green and inclusive future with a transparent and responsible attitude.

Shanghai Junshi Biosciences Co., Ltd.

Board of Directors

March 2025

Materiality Assessment

The Company regularly identifies material topics in ESG that need attention. Through the evaluation and communication with internal and external stakeholders, we prioritize topics based on their impact materiality and financial materiality to finalize the material topic matrix. During the Reporting Period, a total of 24 material topics were identified, including Innovation-driven Development, Technology Ethics, Product Quality, Customer Service, Beneficial Healthcare, and Industry Exchange and Cooperation, etc.

Material Topic Matrix of Junshi Biosciences



Communications with Stakeholders

The Company actively communicates with core stakeholders such as customers, shareholders, government and regulatory agencies, employees, media and the public, suppliers, communities, non-governmental organizations, and institutional investors through a variety of online and offline channels. Through in-depth communication with various parties, the Company fully understands the expectations of stakeholders for the Group's sustainable development and uses them as an important basis for improvement.

Stakeholders	Material Topics of Concern	Main Communication Channels
Shareholders/ Investors	• Corporate Governance • Compliant Operation • Business Ethics • Communications with Stakeholders	• SSE E-Interactive Platform • General Meeting of Shareholders • Regular Reports and Announcements • Performance Briefings • Investor Survey • Investor Emails and Hotlines • Company Website and WeChat Official Account
Government and Regulatory Agencies	• Corporate Governance • Compliant Operation • Business Ethics • Environmental Compliance Management • Energy Utilization • Water Resource Utilization • Waste Treatment • Pollutant Emissions • Response to Climate Change • Circular Economy • Contribution to Society • Rural Revitalization • Beneficial Healthcare • Technology Ethics	• Communication at Meetings • Daily Supervision and Communication • Information Disclosure and Submission

Stakeholders	Material Topics of Concern	Main Communication Channels
Employees	• Protection of Employees' Rights and Interests • Talent Development and Training • Occupational Health and Safety	• Employee symposium • Work Meetings • Employee Training • Employee Activities
Customers	• Customer Service • Product Quality • Innovation-driven Development • Technology Ethics • Data Security and Customer Privacy Protection	• Daily Communication • Customer Service • Quality Management • Satisfaction Management
Suppliers and Partners	• Supply Chain Security • Industry Exchanges and Cooperation	• Supplier Management • Supplier Audit • Industry Exchange and Interaction • Daily Communication
Community and the Public	• Contribution to Society • Rural Revitalization • Beneficial Healthcare	• Public Benefit Activities • Charity Donation

01

Sound Governance

Junshi Biosciences always adheres to the core concepts of compliant operation, continues to improve the corporate governance framework and builds a standardized and efficient operation system. Promoting operational efficiency and enhancing corporate competitiveness with a strong sense of responsibility, we are committed to safeguarding the legitimate rights and interests of shareholders, enhancing the value of the Company, and laying a solid foundation for sustainable development.

Governance Framework

In accordance with the Company Law, the Securities Law, the SSE STAR Market Listing Rules, the HKEX Listing Rules, other applicable laws, regulations, normative documents, as well as the *Articles of Association*, the Company has established a governance framework with a clear division of rights and responsibilities, which consists of the General Meeting of Shareholders, the Board of Directors, the Board of Supervisors, and the Senior Management of the Company. In 2024, the Company continuously strengthened the construction of the governance framework, revised the list of rights and responsibilities from time to time, and improved the governance system to ensure the standardization and effectiveness of corporate governance.



General Meeting of Shareholders

The General Meeting of Shareholders is the highest authority of the Company, responsible for making decisions on major matters of the Company. Shareholders enjoy rights and bear obligations according to the types of shares they hold, and the convening and voting procedures of the General Meeting of Shareholders are in strict compliance with the applicable laws and regulations as well as the Articles of Association. During the reporting period, the Company held 4 General Meetings of Shareholders.

Board of Directors

The Board of Directors, as the core of corporate governance, has decision-making power and strictly implements the resolutions of the General Meeting of Shareholders. The General Manager implements the will of the Board of Directors and is responsible for the management of the Company. The Board of Directors sets up four committees, namely, the Audit Committee, the Nomination Committee, the Strategic Committee, and the Remuneration and Appraisal Committee, and formulates corresponding implementation rules. These committees play an active role in fields such as risk prevention and corporate decision-making, to provide strong support for the steady and healthy development of the Company. During the Reporting Period, the Company held 13 board meetings.

Number of Members in Board of Directors
14

Percentage of Female Directors
29%

Percentage of Independent Directors
36%

Note: As of the end of the Reporting Period

Board of Supervisors

The Board of Supervisors, as the internal supervisory body, is responsible for supervising the performance of functions, financial activities, internal controls, and risk management of directors and senior management, and ensuring the standardization and transparency of corporate governance. During the Reporting Period, the Company held 7 meetings of the Board of Supervisors.

Investor Relations

The Company attaches great importance to the protection of investors' rights and interests. In accordance with applicable laws, regulations, and the *Articles of Association*, the Company has established the *Investor Relations Management System*, continuously improved the investor relations management mechanism, strengthened communication with investors, and effectively safeguarded investors' legal rights and interests. Through enhancing the business training of relevant personnel and other means, the Company improves investor relations management and endeavors to build mutual trust and harmonious investor relations.

The Company actively communicates and interacts with investors through diversified channels and rich forms, and responds to investor concerns in a timely manner.

- Replied to over 110 investor inquiries on platforms such as SSE E-Interactive and SSE Roadshow Center, disclosed 19 voluntary announcements, and actively interacted with investors through channels such as hotline and investor email (info@junshipharma.com).
- Received over 20 visits by domestic, foreign and other investors, including institutional investors and small and medium-sized investors, through brokerage strategy meetings, roadshows, counter-roadshows and corporate surveys.
- Hosted the "2024 Know about Listed Companies" Event, invited investors to conduct on-site surveys at the Lingang Production Base, and engaged in deep discussions on R&D and production conditions.
- Attended the SSE STAR Market 2023 Annual Collective Performance Briefing for Pharmaceutical Companies and 2024 Q1 Performance Briefing, and 2024 Semi-annual Collective Performance Briefing for Pharmaceutical and Biological Products Companies, and held the 2024 Q3 Performance Briefing, to interact and communicate with investors on operating results and financial indicators.
- Produced and disseminated the 2023 performance interpretation video, 2023 performance chart, 2024 interim performance infographic, and 2024 quarterly bilingual business progress reviews 6 times, to provide investors with a more comprehensive and in-depth understanding of the Company's updates.

SSE STAR Market 2024 Semi-annual Collective Performance Briefing for Pharmaceutical and Biological Products Companies

2024 Q3 Performance Briefing at SSE Roadshow Center


"Know About Listed Companies" Event

Compliant Operation

Transparent Disclosure

The Company actively fulfills its information disclosure obligations, effectively protecting the legal rights and interests of the Company and its shareholders, creditors, and other stakeholders. In accordance with the Company Law, the Securities Law, the *Measures for the Administration of Information Disclosure by Listed Companies* and other laws and regulations, we have formulated the *Information Disclosure Management System* to standardize information disclosure and ensure transparency in the Company's operations. In 2024, the Company won the "Golden Bull Award - 2023 Golden Information Disclosure Award" from China Securities Journal. The Company was rated A in the "Evaluation of Information Disclosure Work of Listed Companies in SSE for 2023-2024" by the Shanghai Stock Exchange.

"Golden Bull Award - 2023 Golden Information Disclosure Award" from China Securities Journal

Risk Management and Risk Control

The Company always adheres to compliant operations and is committed to establishing a sound compliance risk management system. To meet the internal control compliance requirements for listed companies, the Company establishes a sound internal control system and conducts a comprehensive assessment of the risks at the corporate level and at the level of major businesses every year in accordance with C-SOX (also known as "Basic Standard for Enterprise Internal Control"). This helps the Company accurately identify major risk points and formulate corresponding control activities to ensure the effectiveness of internal control and the scientificity of risk management.

Quality Risk Management Seminar

Tax Management

In tax management, the Company diligently fulfills its tax declaration and payment obligations in strict compliance with national and local tax laws and regulations. By building a systematic tax management system and rules, the Company further standardizes tax management processes and ensures tax compliance. During the Reporting Period, no tax disputes occurred in the Company.

Business Ethics

The Company attaches great importance to anti-commercial bribery and anti-corruption work, abides by medical and ethical guidelines as well as applicable laws and regulations such as the *Anti-Unfair Competition Law of the People's Republic of China* and the *Interim Provisions on Banning Commercial Bribery*, and incorporates the principle of good faith and anti-commercial bribery provisions into its *Articles of Association*. By enhancing system development, strengthening employee training, establishing multi-channel reporting mechanisms, enforcing strict management of meetings and events, and implementing full-process compliance controls, the Company has set clear compliance requirements in aspects such as anti-corruption, anti-money laundering, and anti-monopoly, thus ensuring comprehensive compliance in its operations. The Company resolutely eliminates any unfair competition with a "zero tolerance" attitude, to ensure the transparency and fairness of business activities. All employees of the Company have signed the *Commitment to the Code of Business Conduct and Professional Ethics*, laying a solid foundation for the sustainable development of the Company. During the Reporting Period, the Company established the Group Compliance Department responsible for developing systems for compliance with business ethics.

The Company has set up and publicized a special mailbox for compliance, and encouraged employees and stakeholders to report malpractices or violations through phone, letters, WeChat, and the "Integrity Junshi" email. The Compliance Department of the Group will keep the information of the whistleblower strictly confidential, and will hold the investigator accountable for any leakage resulting in adverse consequences. During the Reporting Period, the Company found no instances of commercial bribery or corruption, nor any lawsuits or significant administrative penalties arising from unfair competition.

The Company strengthens compliance with business ethics through various measures, such as regularly publishing integrity posters, offering compliance training, and inviting law firms to provide anti-corruption training for directors and supervisors. During the Reporting Period, the Company held a Cultural Month Event to promote integrity and compliance, and provided 29 anti-commercial bribery and anti-corruption training sessions for 100% of directors, supervisors, senior management and employees.

provided

29 anti-commercial bribery and anti-corruption training sessions

100%

of directors, supervisors, and employees

02

Product Research and Development

Always adhering to its original mission, Junshi Biosciences prioritizes patients' life and health, makes every effort to build a high-quality management system, and strictly complies with all laws and regulations to ensure product quality and safety. The Company upholds the philosophy of innovation, continuously advances R&D of pipeline, pays attention to the protection of intellectual property rights, strictly abides by the ethics of science and technology, and actively acts in all dimensions to promote the industry exchanges and enhance the welfare of patients.

Product Responsibility

In the healthcare field, the Company focuses on patients' life and health, strives to build a comprehensive quality management system, and strictly follows domestic and international regulations, to ensure the safety and efficacy of its products. Moreover, the Company attaches high importance to information security, establishes a professional protection system, and comprehensively improves its information security capabilities through team building, employee training and third-party cooperation. For supply chain management, the Company implements full lifecycle management, strengthens auditing and environmental protection requirements, and ensures supply chain compliance and transparency, to safeguard patients' health.

Key Performance

Product Recall Rate 0%	Pharmacovigilance Training Coverage Rate 100%	Total Number of Participants in Pharmacovigilance Training 2,743 Persons	Number of Confirmed Data Security Incidents 0 Cases
Specific Amount Involved in Data Security Incidents 0 In 10,000 yuan	Number of Confirmed Customer Privacy Breach Incidents 0 Cases	Specific Amount Involved in Customer Privacy Breach Incidents 0 In 10,000 yuan	

Product Quality

The Company always regards product quality as the fundamental guarantee for patients' life and health, builds and continuously improves the quality management system in accordance with the quality policy of "Prioritizing Quality, Respecting Life, Keeping Innovation, and Pursuing Excellence". The Company strictly abides by the existing *Pharmaceutical Administration Law of the People's Republic of China*, the *Good Clinical Practice*, the *Good Manufacturing Practice of Medical Products*, the *Measures for the Administration on Report and Monitoring of the Side Effect of Pharmaceuticals*, the *Regulations on the Supervision and Management of Drug Quality Safety Responsibilities by Drug Market Authorization Holders*, the *Announcement of National Medical Products Administration on Strengthening the Supervision and Administration of Entrusted Manufacturing by Drug Market Authorization Holders*, the *Measures for the Quality Supervision and Administration of the Distribution and Use of Medicinal Products* and other domestic regulations, as well as EU pharmaceutical management regulations, US federal regulations, and the *Harmonized Tripartite Guideline of International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use* (ICH).

In accordance with the above laws and regulations, the Company has formulated and improved its *Quality Manual* to clarify quality requirements in aspects such as the quality management system, quality control system, production systems, as well as the management responsibilities of each quality-related department, and ensure that quality information related to product quality and quality management systems is promptly collected and connected with subsidiaries. The Suzhou Wujiang Production Base and Shanghai Lingang Production Base of the Company have obtained GMP certificates by the National Medical Products Administration (the"NMPA"). While cultivating the domestic market, the Company is actively expanding overseas markets and optimizing the global supply layout, to provide high-quality and effective medicines to patients worldwide. So far, the Suzhou Wujiang Production Base has obtained GMP certifications from the United States and the European Union. Currently, commercial batches of toripalimab for the United States, India, Hong Kong SAR of China, and other regions are produced by Suzhou Wujiang Production Base.

The Company has established a Corrective Action and Preventive Action (CAPA) quality management process covering links such as deviation handling, product quality review, risk assessment, and continuous improvement. The Quality Control Department is involved in the whole production process and conducts regular preventive tests to ensure that potential problems are detected and solved in a timely manner. Before the delivery of the finished products, the Quality Control Team always carries out a final inspection to confirm that such finished products are qualified to be sold to the public. For products already on the market, the Company conducts an annual product quality review, and makes targeted improvements based on the results to continuously enhance product quality. Additionally, the Company has formulated systems such as the *Complaint Management System*, the *Product Recall System* and the *Return Management System, the Drug Quality Related Safety Information Management System* to standardize the handling process of related incidents. We also regularly organize emergency response drills for product recall and drug safety incidents. During the Reporting Period, no product recalls required for safety and health reasons occurred in the Company.

The Company has built and improved a pharmacovigilance system covering the work protocols and requirements of drug safety activities in accordance with the *Lifecycle Management of Procedural Documents*, and set up the Drug Safety Department responsible for the management of drug safety information, including the regular retrieval and processing of scientific literature, the writing of safety update reports, and the assessment and management of safety signals and safety risks, to strengthen the drug safety defense across multiple dimensions. During the Reporting Period, the Company passed a special inspection on pharmacovigilance conducted by the Shanghai Drug and Medical Device Adverse Reaction Monitoring Center.

During the Reporting Period, the Drug Safety Department provided the training on annual safety information reporting responsibility for all employees in accordance with the *Safety Information Reporting Responsibilities for Spontaneous Reporting Sources*, which covers the Company's pharmacovigilance responsibilities, as well as the responsibilities of employees to report drug safety information in their daily work. A total of 2,743 in-service employees participated in the training.

Customer Service

The Company values customer service and feedback from customers, and actively builds a bridge of communication with customers. The Company has developed the *Standard Operating Procedures for Customer Complaint Management* and the *Standard Operating Procedures for Management of Adverse Reactions of Drugs* with respect of customer information and feedback, and established an adverse reaction monitoring system to track customer experiences with the products. Employees, partners, or third-party representatives must report drug safety issues within 24 hours after discovery through the hotline, the reporting page on the Company's official website, or the email address of the Drug Safety Department. The Drug Safety Department is responsible for handling and evaluating this information, following up on missing or important updates, and submitting reports to regulatory authorities and partners as required. For death cases or mass adverse events in the Chinese Mainland, the Company has established an investigation mechanism to complete and submit investigation reports to relevant departments as required.

Adverse Event Reporting Page on Official Website

Data Security and Customer Privacy Protection

The Company has built an information security protection system and set up a specialized information security team under the Information Technology Department, to safeguard the Company's information security, network protection and the integrity of information systems and data assets. The Company organizes data security training for new employees, information security awareness training for all employees, and regular phishing drills. Additionally, the Company collaborates with third-party IT organizations to conduct penetration testing to further enhance its security protection capabilities. During the Reporting Period, no data breaches occurred in the Company.

Data Security Management Measures:

- Data encryption: use transmission layer (TLS/SSL) and storage encryption technologies to protect the security of data during transmission and storage.
- Access control: adopt multi-factor authentication, role-based access control, and process control mechanisms to ensure that only authorized personnel can access sensitive information.
- Network security protection: deploy firewalls, enable Intrusion Detection/Prevention System (IDS/IPS) modules, and conduct network isolation based on business needs.
- Data masking: use de-identified personal information during data processing to reduce the risk of leaks.
- Regular vulnerability scanning and patch updates: identify and fix potential security vulnerabilities in the system.
- Data backup: perform regular backups with technical solutions based on business requirements.

The Company attaches importance to the protection of customers' rights and interests. In strict compliance with the *Biosafety Law of the People's Republic of China* and the *Personal Information Protection Law of the People's Republic of China*, the Company has formulated the standards and operating procedures for the *Interaction and Communication with External Institutions and Personnel*, which require the business personnel of the Company to strictly follow the requirements for the protection of customers' privacy. In particular, regarding human genetic resource management, the Company strictly prohibits illegal collection, unlawful sharing, and unauthorized cross-border transfer of human genetic resources. In terms of personal information processing, the Company focuses on protecting sensitive personal information related to aspects such as biometrics and healthcare, and makes every effort to protect the privacy and security of its customers.

Supply Chain Management

The Company strictly fulfills the responsibilities of the marketing authorization holder (MAH) of medical products, establishes a sound *supplier management system*, and formulates the systems such as the Supplier Management System, the *Supplier Audit System* and the *Standard Operation Procedure for Material Procurement*. Through risk level assessments and classified management of suppliers, the Company has implemented full lifecycle management from the selection, evaluation, use, maintenance, to suspension/ withdrawal of suppliers. For different categories of suppliers, the Company has established corresponding audit frequencies and methods. The audit content covers the authenticity of suppliers' qualification documents, personnel organization, plant and equipment, supply chain management, production management, quality control, data reliability, and sterility assurance. Deficiencies identified during the audit process will be classified and addressed, and targeted measures will be taken if necessary. The Company requires all suppliers to sign the *Integrity Agreement*, and suppliers who have not signed it are required to provide written explanations, thus safeguarding the fairness and integrity of cooperation at the institutional level. What's more, the Company has set environmental protection requirements for material suppliers, requiring them to provide relevant testing reports to prove their compliance with environmental standards. These measures have strengthened supplier management from multiple dimensions, improved standardization and transparency, ensured fairness and integrity of cooperation at the institutional level, and supported the green and healthy development of the Company's supply chain.

The Company attaches great importance to collaboration with suppliers and is committed to establishing long-term stable cooperative relationships to address supply chain uncertainties. To this end, the Company signs annual framework agreements with core suppliers and includes them in the annual or strategic supplier system, to ensure the resilience and continuity of the supply chain. The Company regularly provides suppliers with training on legal compliance, quality improvement and SRM system synergy to help them improve their business capabilities and meet the Company's requirements in terms of quality and efficiency. During the Reporting Period, the Company optimized existing SRM procurement management system, provided operational training to suppliers to ensure that they could better adapt to the new system, and proceeded procurement operations proceeded smoothly without delays affecting production, clinical trials, or engineering construction.

As of the end of the Reporting Period, the Company had 2,298 main suppliers, of which approximately 94% were domestic suppliers. The Company encourages the preferential use of local suppliers to promote local employment as well as technological and economic development.

the Company had

2,298 main suppliers

of which approximately

94% were domestic suppliers

Innovation-driven Development

In the field of biopharmaceuticals, innovation is the lifeblood for the survival of enterprises. Upholding the philosophy of “adhering to innovation-driven development”, the Company actively explores cutting-edge technologies, builds professional R&D teams, and strives to solve more medical challenges. We attach importance to the protection of intellectual property rights, build a strict protection system, and strictly abide by the ethics of science and technology to ensure that R&D is in line with ethical norms. The Company also actively carries out industry communication, participates in academic seminars, and works hand in hand with its peers to promote the industry's development.

Key Performance

Number of patents held

175 Cases

Number of invention patents held

70 Cases

Number of new patents added in the year

32 Cases

Number of patents under review

284 Cases

Number of copyrights held

10 Cases

R&D and Innovation Capabilities

The Company has formed a strong R&D team and collaborates with leading global companies to address unmet clinical needs. The Company established an R&D center in the United States to absorb advanced overseas technologies and enhance R&D capabilities. Till now, the R&D scope of the Company has expanded from monoclonal antibodies to small molecule drugs, polypeptide drugs, antibody-drug conjugates (ADCs), bispecific or multispecific antibody drugs, bispecific antibody-drug conjugates, fusion proteins, nucleic acid drugs, etc. The Company is exploring innovative therapies for cancer and autoimmune diseases, making it a company with a diversified R&D system.

The Company has established the Innovation Research Institute and the Clinical R&D Department, covering the full chain from drug discovery, process development, preclinical research, to clinical trials. The R&D team is experienced, and its core members are mostly from renowned domestic and international research institutions and multinational pharmaceutical companies, with solid theoretical and practical foundations. By formulating standardized procedures such as the *R&D Project Life Cycle Management Procedures*, the *R&D Team Management Procedures* and the *R&D Project Centralized Review Meeting Management Procedures*, the Company has clarified responsibilities and communication requirements, and significantly improved R&D efficiency and management levels. For R&D personnel, the Company has established a performance evaluation system to reward employees with outstanding performance and award them the title of “Excellent Employees”. In addition, the Company also awards the title and rewards of “Project Star” based on employees' performance in R&D projects.

During the Reporting Period, the Company actively implemented the Action of “Enhancing Quality and Efficiency with a Focus on Returns”, continuously strengthened the control of expenses and focused resources on more promising R&D projects. The Company made a number of important progresses in the R&D projects. The R&D expenses amounted to RMB 1.275 billion, which was used for early drug R&D, clinical trials and the recruitment of professional R&D talents. The continuous investment in R&D has strongly supported the R&D of the Company's innovative drug projects.

As of the end of the Reporting Period, the Company had 4 commercialized drugs (TOUYI®, JUNMAIKANG®, MINDEWEI®, and JUNSHIDA®). Nearly 30 investigational drugs are undergoing clinical trials, and over 20 investigational drugs are at a preclinical development stage. The pipeline of investigational drugs covers five major therapeutic fields, including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurologic diseases, and infectious diseases.

Key Projects Entering the Clinical R&D Stage (As of 27 March 2025)

君实生物 TopAlliance

Phase I/II		Phase III	Approval for marketing
JS213 PD-1 × IL2	**JS207** PD-1 x VEGF	**Tifcemalimab** BTLA	**Toripalimab** PD-1
JS212 EGFR × HER3 ADC	**JS015** DKK1	**JS001sc** PD-1	**Adalimumab** TNF-α
JS006 TIGIT	**JS107** Claudin18.2 ADC	**JS005** IL-17A	**Deuremidevir Hydrobromide Tablets** RdRp
JS007 CTLA-4	**JS203** CD3 × CD20		**Ongericimab** PCSK9
JS009 CD112R	**JS105** PI3K-α		
JS112 Aurora A	**JS110** XPO1		
JS214 VEGF × TGF-β	**JS111** EGFR exon 20		
JS010 CGRP	**JS125** HDACs		
UBP1213sc BLyS	**JT002** small nucleic acid immunomodulator		
.....			

○ Oncology ● Metabolism
● Immunology ● Neurologic
● Infectious disease

During the reporting period, many remarkable academic achievements were made with the Company's innovative products, such as toripalimab and tifcemalimab (an anti-BTLA monoclonal antibody). Specifically, the research results of toripalimab have been published repeatedly in international authoritative journals and academic conferences such as *JAMA* and *Nature Medicine*. Toripalimab leads to breakthroughs in the treatment of many cancers including lung cancer, breast cancer, esophageal cancer, nasopharyngeal cancer, liver cancer, and colorectal cancer, and sets new records in prolonging survival time.

International Academic Conferences

May 2024

Multiple studies of toripalimab were selected for presentation at the 119th (2024) Annual Meeting of the American Urological Association (AUA) and the 2024 Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO). These studies highlighted the potential of toripalimab in the treatment of tumors of urinary system and its combination with radiotherapy/chemotherapy in the treatment of cervical cancer, colorectal cancer, and nasopharyngeal cancer.

June 2024

Over 30 studies of toripalimab (anti-PD-1 monoclonal antibody) and tifcemalimab (anti-BTLA monoclonal antibody), which covered different populations with nasopharyngeal cancer, lung cancer, esophageal cancer, bladder cancer, melanoma and other tumors, were selected for presentation at the 2024 Annual Meeting of American Society of Clinical Oncology (ASCO), to explore a variety of combinations of therapies.

September 2024

Updated data from a Phase I/II clinical study of tifcemalimab in combination with toripalimab in refractory extensive-stage small-cell lung cancer was successfully selected for oral report at the World Congress on Cancer (WCLC) 2024. Multiple studies of toripalimab were also included in this conference.

September 2024

18 studies of toripalimab were included in the 2024 Annual Meeting of the European Society for Medical Oncology (ESMO). These studies covered head and neck cancer, lung cancer, breast cancer, gastrointestinal tumors, urological tumors and other tumors, involved various combination therapies and explored new directions in immunotherapy.

December 2024

Multiple research results of toripalimab and tifcemalimab were included for representation at the European Society for Medical Oncology Asia (ESMO Asia) Congress and the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress, covering fields such as head and neck cancer, lung cancer, gastrointestinal tumors, urological tumors, and exploring new strategies in immunotherapy.

October 2024

6 research results of toripalimab were presented at the 66th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in 2024 in the form of oral reports and posters, bringing international scholars the latest cutting-edge results of combination therapies such the radiotherapy combined with toripalimab in gastrointestinal tumors and kidney cancer.

September 2024

Multiple research outcomes of toripalimab were selected for oral reports at the 27th National Clinical Oncology Conference and the 2024 CSCO Academic Annual Meeting, of which 7 were selected for oral report, covering head and neck cancer, melanoma, gastrointestinal tumors, breast cancer, urological tumors, soft tissue sarcoma, and other tumors.

International Authoritative Journals

January 2024

The results of a Phase III clinical study of toripalimab in combination with albumin-bound paclitaxel (nab-P) for the treatment of newly diagnosed stage IV or recurrent metastatic triple-negative breast cancer (TNBC) were published in the *Nature Medicine* (IF:58.7). This marks another international academic recognition for the TORCHLIGHT study, following its prominent presentation at the Late-Breaking Abstracts (LBA) of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The study concluded that toripalimab in combination with nab-P significantly improved PFS, providing a promising new treatment strategy for patients with PD-L1-positive newly diagnosed stage IV or recurrent metastatic triple-negative breast cancer.


nature medicine

Article https://doi.org/10.1038/s41591-023-02677-x

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

January 2024

The Phase III clinical study of toripalimab combined with chemotherapy for the perioperative treatment of resectable non-small-cell lung cancer (NSCLC) (the "NEOTORCH Study") was published in the *Journal of the American Medical Association* (JAMA, IF:63.1), the first immunotherapy study of perioperative (including neoadjuvant and adjuvant) lung cancer published in the main issue of JAMA in the world. Previously, the NEOTORCH Study had released its interim analysis results on the Event Free Survival (EFS) at the 2023 ASCO Plenary Series held in April 2023, and at the ASCO Annual Meeting.


JAMA | Original Investigation

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer
The Neotorch Randomized Clinical Trial

Shun Lu, MD; Wei Zhang, PhD; Lin Wu, PhD; Wenxiang Wang, PhD; Peng Zhang, PhD; and the Neotorch Investigators

July 2024

The results of a randomized, Phase II clinical study of TORCH short-course radiotherapy in combination with CAPOX and toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer were published in the *Journal of Clinical Oncology*, an international top oncology journal Journal of Clinical Oncology (IF:42.1). TORCH is the first randomized clinical study to report a novel total neoadjuvant chemoradiotherapy combined with immunotherapy (iTNT) and the selective "wait and watch (W&W)" strategy for pMMR/MSS (mismatch repair proficient or microsatellite stable) locally advanced rectal cancer (LARC). The study explored the efficacy and safety of different combination therapy regimens for iTNT. Group A received short-course radiotherapy followed by toripalimab combined with chemotherapy for consolidation treatment, while Group B received underwent two courses of toripalimab combined with chemotherapy for induction treatment, and then short-course radiotherapy and immune therapy. The results indicated that both regimens achieved a complete response (CR) rate of over 50%, with more than 80% of patients achieving organ function preservation.


Journal of Clinical Oncology
An American Society of Clinical Oncology Journal

ORIGINAL REPORTS | July 01, 2024

Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer

July 2024

The results of a multicenter, randomized, Phase-II clinical study (NCT04389073) comparing different combination immunotherapy regimens for advanced HER2-negative breast cancer were published in *Nature Medicine* (IF:58.7), one of the world's top medical journals. The study compared the efficacy and safety of conventional chemotherapy, metronomic chemotherapy, anti-angiogenic drugs, and toripalimab-based combination regimens for advanced HER2-negative breast cancer. The results revealed that, compared to traditional chemotherapies, toripalimab combined with VEX (vinorelbine + cyclophosphamide + capecitabine) metronomic chemotherapy was more effective and less toxic, significantly improving disease control rate (DCR) and progression-free survival (PFS).

August 2024

The interim results of a single-center, randomized, controlled Phase III clinical study (HCHTOG1909 study, NCT04280822) were published in Cancer Communications (IF:20.1). This study aimed to explore the efficacy and safety of neoadjuvant toripalimab combined with chemotherapy versus neoadjuvant chemotherapy alone for resectable locally advanced ESCC. The study results indicated that the combination of toripalimab with paclitaxel and cisplatin as a neoadjuvant therapy exhibited a trend towards improved overall survival (OS), and demonstrated benefits in secondary endpoints such as pCR rate, R0 resection rate and MPR rate, and that the safety profile was consistent with previous results, without additional surgical risks. The findings are expected to potentially change the perioperative treatment landscape for ESCC.

September 2024

The exploratory biomarker analysis results from a Phase-III, randomized controlled clinical study (the "CHOICE-01 Study") on toripalimab in combination with chemotherapy for the first-line treatment of advanced non-small cell lung cancer ("NSCLC") were published in Cancer Cell (IF:48.8), one of the world's renowned journals. Through a comprehensive analysis of dynamic pan-genomic characteristics from the CHOICE-01 Study, a blood-based genomic immune subtype (bGIS) method based on ctDNA was developed to provide a new strategy for refined stratification in first-line combined immunochemotherapy for advanced NSCLC, and point the way for further prospective studies based on the stratification strategy in the future.


Article | Published: 05 July 2024

Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial

Hongnan Mo, Yongpei Yu, Xiaoying Sun, Hewei Ge, Lanlan Yu, Xiuwen Guan, Jingtong Zhai, Aihua Zhu, Yuhan Wei, Jinjing Wang, Xiaoyan Yan, Haili Qian, Binghe Xu & Fei Ma


Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial

Yan Zheng[1] | Guanghui Liang[1] | Dongfeng Yuan[1] | Xianben Liu[1] | Yufeng Ba[1] | Zimin Qin[1] | Sining Shen[1] | Zhenxuan Li[1] | Haibo Sun[1] | Baoxing Liu[1] | Quanli Gao[2] | Peng Li[1] | Zongfei Wang[1] | Shilei Liu[1] | Jianping Zhu[1] |


Cancer Cell

Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer

Published on September 9, 2024
DOI: https://doi.org/10.1016/j.ccell.2024.08.013

September 2024

The latest data from a Phase Ib/II clinical study of toripalimab combined with surufatinib and chemotherapy (etoposide + cisplatin, EP) for the first-line treatment of advanced small-cell lung cancer (SCLC) was published in the Signal Transduction and Targeted Therapy (STTT, IF:40.8), an internationally renowned journal. The results showed that the four-drug and three- combination regimen of toripalimab, surufatinib, and EP for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) achieved an objective response rate (ORR) of 97.1%, a disease control rate (DCR) of 100%, a median progression-free survival (mPFS) of 6.9 months, and a median overall survival (mOS) of 21.1 months. This is the longest median survival reported to date in clinical trials of the first-line treatment for advanced SCLC, setting a new benchmark for survival benefits in patients. The preliminary data of this study were selected for presentation at the ESMO Immuno-Oncology Congress (ESMO-IO) 2022 and the ESMO Immuno-Oncology Congress (ESMO-IO) 2023.


Signal Transduction an

ARTICLE OPEN

Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial

Yaxiong Zhang, Yan Huang, Yunpeng Yang, Yuanyuan Zhao, Ting Zhou, Gang Chen, Shen Zhao, Huaqiang Zhou,

October 2024

The results of a Phase-II NEOTAX study of neoadjuvant treatment with toripalimab and axitinib for renal carcinoma with inferior vena cava tumor thrombus (IVCTT) were officially published in the Signal Transduction and Targeted Therapy (STTT, IF:40.8), one of the world's renowned journals. NEOTAX is the first clinical study in China to target the downgrading of vena cava tumor thrombus. The results showed that toripalimab combined with axitinib as neoadjuvant therapy for clear cell renal cell carcinoma (RCC) with IVCTT achieved a tumor thrombus downstaging rate of up to 44.0%. The therapy effectively reduced surgery scope, surgery difficulty and perioperative risks, improved surgical success rates, and brought patients a better survival prognosis. Previously, the results of the study were selected for presentation at the 2024 ESMO Annual Meeting.

November 2024

The results of the Phase III EXTENTORCH study on the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) with toripalimab combined with chemotherapy were published in the *JAMA Oncology* (IF:22.5), a top international oncology journal. As the first Phase III clinical study of an anti-PD-1 monoclonal antibody in the ES-SCLC field to successfully achieve positive results for both pre-set primary endpoints, the EXTENTORCH study also presented biomarker analysis results, providing richer evidence for the precision treatment of SCLC. The study was selected for oral report as LBA at the ESMO Congress 2023.


JAMA Oncology

RCT: Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer

POPULATION
366 Men, 76 Women

INTERVENTION
442 Participants randomized
All participants received chemotherapy with etoposide and carboplatin or cisplatin (EP)
223 Toripalimab
Intravenous (IV) toripalimab, 240, mg plus EP every 3 wk for ≤4-6 cycles, followed by toripalimab maintenance

FINDINGS
The addition of toripalimab to chemotherapy as first-line treatment in adults with extensive-stage small cell lung cancer significantly prolonged both PFS and OS

December 2024

The results of a Phase-II randomized controlled double-blind study on neoadjuvant and adjuvant toripalimab combined with concurrent chemoradiotherapy for the treatment of high-risk locally advanced nasopharyngeal carcinoma were officially published in Lancet Oncology (IF:41.6), a leading international oncology journal. The study first revealed that adding neoadjuvant and adjuvant toripalimab to concurrent chemoradiotherapy significantly improved the survival rate of patients with high-risk locally advanced nasopharyngeal carcinoma, reducing the risk of disease progression or death by 60%. In terms of safety, no new safety signals were observed in the toripalimab combination treatment group, and the incidence of grade ≥3 treatment-related adverse events was similar between the two groups.

THE LANCET
Oncology

This journal | Journals | Publish | Clinical | Global health | Multimedia | Events | About

ARTICLES · Online first, November 07, 2024

Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blinc placebo-controlled, phase 2 trial

Sai-Lan Liu, MD [a,f,*] · Xiao-Yun Li, MD [a,f,*] · Jin-Hao Yang, MD [a,f,*] · Dong-Xiang Wen, MD [a,f,*] · Shan-Shan Guo, MD [a,f,*] · Li-Ting Liu, MD [a,f,*] · Yi-Fu Li, MD [a,f,*] · Mei-Juan Luo, MD [b,f] · Si-Yi Xie, MD [a,f] · Yu-Jing Liang, MD [b,f] · Xue-Song Sun, MD · Zhen-Chong Yang, MD [c,f] · Xiao-Fei Lv, MD [b,f] · Prof Dong-Hua Luo, MD [a,f] · Ji-Bin Li, PhD [d,f] · Prof Qing Liu, PhD [d,f] · Pa · Prof Ling Guo, MD [a,f] · Prof Hao-Yuan Mo, MD [a,f] · Prof Rui Sun, MD [a,f] · Qi Yang, MD [a,f] · Kai-Qi Lan, MD [a,f] · Guo-Dong · Ru Li, MD [a,f] · Prof Chong Zhao, MD [a,f] · Prof Rui-Hua Xu, MD [e,f] · Prof Qiu-Yan Chen, MD [a,f,†] · Prof Lin-Quan Tang, MD · Prof Hai-Qiang Mai, MD [a,f,†] Show less

June 2024



Abstract Number
8089

Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study

Yongfeng Yu[1], Yan Yu[2], Yan Zhang[3], Wei Zhang[4], Dongqing Lv[5], Yuan Chen[6], Dingzhi Huang[7], Mingjun Zhang[8], Yongsheng LI[9], Dairong LI[9], Junzhen Gao[10], Lin Wu[11], Zhiyong He[12], Jianhua Shi[13], Mingfang Zhao[14], Ameen Lu[15], Chunyue Wang[16], Hui Zhu[17], Shun Lu[17]*, Shanghai Junshi Biosciences[18]

[1]Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China; [2]Hanlin Medical University Cancer Hospital, Harbin, China; [3]Inner China Hospital, Sichuan University, Chengdu, China; [4]First Affiliated Hospital of Nanchang University, Nanchang, China; [5]Zhejiang Taizhou Hospital, Taizhou, China; [6]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; [7]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; [8]Second Affiliated Hospital of Anhui Medical University, Hefei, China; [9]Chongqing University Cancer Hospital, Chongqing, China; [10]The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China; [11]Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China; [12]Fujian Cancer Hospital, Fuzhou, China; [13]Jilin Cancer Hospital, Linyi, China; [14]The First Affiliated Hospital of China Medical University, Shenyang, China; [15]The second Affiliated Hospital of Nanchang University, Nanchang, China; [16]The First Affiliated Hospital of Xiamen University, Xiamen, China; [17]Shandong Provincial Institute of Cancer Prevention and Treatment, Jinan, China; [18]Shanghai Junshi Biosciences, Shanghai, China; *Corresponding author

Introduction

- The B- and T-lymphocyte attenuator (BTLA) is an inhibitory receptor expressed on T and B lymphocytes with sequence similarities to programmed death 1 (PD-1)[1].
- Co-blockade of the BTLA and PD-1 pathways effectively improves T cell activation[2,3] and exserts synergy ex vivo using lymphocytes from cancer patients[4].
- Tifcemalimab (JS004 or TAB004), a humanized IgG4 monoclonal antibody that binds BTLA and blocks its interaction with its ligand Herpesvirus Entry Mediator (HVEM).
- In a previous phase I/II study, tifcemalimab has shown preliminary anti-tumor activities in combination with toripalimab (anti-PD-1) as a later line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC)[5].
- We further conducted a multi-cohort phase Ib/II study (NCT05664971) to evaluate the safety and efficacy of tifcemalimab combined with toripalimab and chemotherapy as a 1st line treatment for patients with advanced lung cancer.
- Here, we report the preliminary results from the ES-SCLC cohort.

Methods

- The study design of cohort 5 of this multicenter, open-label, multi-cohort, phase Ib/II study is illustrated in **Fig 1**.

Figure 1. Study design

- **Primary endpoints:** Safety per NCI-CTCAE v5.0 and ORR by investigator per RECIST v1.1
- **Secondary endpoints:** DCR, DoR, TTR, PFS, and OS
- **Safety analysis set (SAS):** Patients who received at least 1 dose of tifcemalimab
- **Efficacy analysis set (EAS):** Patients who received at least 1 dose of tifcemalimab and had at least one post-treatment tumor assessment.

Baseline Characteristics

- As of March 26, 2024, 44 patients with ES-SCLC were enrolled and received the combination therapy, the median follow-up duration was 4.2 months.
- The median age of the patients was 65.5 (range 48-73) years, and 84.1% (37/44) were males (**Table 1**).

Table 1. Demographics and baseline characteristics

Characteristics	Patients (n=44)
Median age (range), years	65.5 (48-73)
Male, n (%)	37 (84.1)
ECOG PS, n (%)	
0	2 (4.5)
1	42 (95.5)
TNM stage, n (%)	
IIIA	1 (2.3)
IIIB	2 (4.5)
IIIC	7 (15.9)
IVA	15 (34.1)
IVB	19 (43.2)

Safety

- Adverse Events (AEs) summary and the commonly reported AEs were listed in **Table 2** and **Table 3**.
- Forty-three (97.7%) patients experienced treatment-emergent adverse events (TEAEs), and 39 (88.6%) experienced tifcemalimab-related TEAEs. Grade ≥3 TEAEs occurred in 39 (88.6%) patients.
- Sixteen (36.4%) patients had serious TEAEs. TEAE led to 2 permanent discontinuation of tifcemalimab treatment, and 1 permanent discontinuation of toripalimab treatment.
- Immune-related AEs (irAEs) of any grade were reported in 13 (29.5%) patients, while grade ≥3 irAEs occurred in 4 (9.1%) patients.

Table 2. Overall summary of TEAEs and irAEs (SAS, n=44)

	n (%)
All grade TEAEs, any cause	43 (97.7)
Tifcemalimab-related	39 (88.6)
Toripalimab-related	37 (84.1)
Chemotherapy-related	43 (97.7)
Grade ≥3 TEAEs	39 (88.6)
Tifcemalimab-related	20 (45.5)
Toripalimab-related	20 (45.5)
Chemotherapy-related	36 (81.8)
Serious TEAEs	16 (36.4)
Tifcemalimab-related	6 (13.2)
Toripalimab-related	7 (15.9)
Chemotherapy-related	10 (22.7)
TEAEs leading to withdrawal or dose interruption	
TEAEs leading to withdrawal from tifcemalimab	2 (4.5)
TEAEs leading to withdrawal from toripalimab	1 (2.3)
TEAEs leading to withdrawal from chemotherapy	1 (2.3)
TEAEs leading to dose interruption from tifcemalimab	4 (9.1)
TEAEs leading to dose interruption from toripalimab	4 (9.1)
TEAEs leading to dose interruption from chemotherapy	17 (38.6)
TEAEs leading to death from any study treatment	0
All-grade irAEs	13 (29.5)
Grade ≥3 irAEs	4 (9.1)
Infusion reactions	4 (9.1)

Table 3. TEAEs occurring in ≥10% patients (SAS, n=44)

TEAEs	Grade ≥3, n (%)	Any grade, n (%)
White blood cell decreased	10 (22.7)	39 (88.6)
Neutrophil count decreased	24 (53.6)	36 (81.8)
Anemia	6 (13.6)	33 (75.0)
Platelet count decreased	11 (25.0)	29 (65.9)
Hyponatremia	2 (4.5)	12 (27.3)
Weight loss	0	10 (22.7)
Hypertriglyceridemia	1 (2.3)	9 (20.5)
Hypercholesterolemia	0	9 (20.5)
Alanine aminotransferase increased	0	9 (20.5)
Hypothyroidism	0	9 (20.5)
Rash	2 (4.5)	9 (20.5)
Aspartate aminotransferase increased	1 (2.3)	8 (18.2)
Hyperthyroidism	0	7 (15.9)
Alopecia	1 (2.3)	7 (15.9)
Constipation	0	6 (13.6)
Hematuria	1 (2.3)	6 (13.6)
Hyperglycemia	0	5 (11.4)
Alkaline phosphatase increased	0	5 (11.4)
Hypoalbuminemia	0	5 (11.4)
Hypomagnesemia	0	5 (11.4)
Hyperuricemia	0	5 (11.4)

Conclusions

- **Tifcemalimab in combination with toripalimab and chemotherapy showed a manageable safety profile as a 1st line treatment for patients with ES-SCLC.**
- **The combination demonstrated promising antitumor activity with an ORR of 86%. A trend of higher response rate in HVEM or PD-L1 positive SCLC patients was observed.**
- **Continued follow-up is ongoing for additional safety and efficacy (PFS and OS) evaluation.**

Corresponding to shun_lu1964@hotmail.com

Antitumor Activity

- With a median follow-up time of 4.2 months, the ORR was 86.0%, and the DCR was 100% in all patients (**Table 4, Fig 2**).
- Median DoR was 4.3 months in all patients (**Fig 3**).
- Median PFS and OS were 5.4 (95% CI 4.2, 7.6) months and NE (95% CI 7.5, NE), respectively (**Fig 4, 5**).

Table 4. Antitumor activity (EAS, n=43)

Best overall response*, n (%)	
Complete response	0
Partial response	37 (86.0)
Stable disease	6 (14.0)
Progressive disease	0
NE	1 (2.3)
ORR† (CR+PR), n (%, 95% CI)	37 (86.0, 72.1-94.7)
DCR‡ (CR+PR+SD), n (%, 95% CI)	43 (100, 91.9-100.0)
Median DoR, months (95% CI)	4.3 (4.1-NE)
Median PFS, months (95% CI)	5.4 (4.2-7.6)
Median OS, months (95% CI)	NE (7.5-NE)

* Unconfirmed; NE, not evaluable

Figure 2. Maximum tumor reduction from baseline (EAS, n=43)

Figure 3. Duration of treatment and response (EAS, n=43)

Figure 4. KM plot of PFS

Figure 5. KM plot of OS

Biomarker Analyses

- HVEM and PD-L1 IHC staining were performed on tumor samples using validated assays. HVEM IHC shows membrane staining on tumor and immune cells (**Fig 6**).
- A trend of higher response rate in HVEM or PD-L1 positive patients was observed (positive defined as CPS ≥1, **Fig 2**).

Figure 6. Representative Results of HVEM IHC Staining

References

1. Watanabe N, et al. Nat Immunol 2003; 4(7):670-679.
2. Fourcade J, et al. Cancer Res 2012;72(5):887-896.
3. Hwang HJ, et al. Immun Inflamm Dis 2021; 9(1):274-287.
4. Choi J, et al. Oncoimmunology 2021; 14(5):e1971-3717.
5. Ying Cheng, et al. J Clin Oncol 41, 2023 (suppl 16; abstr 8576)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; ORR, objective response rate; DCR, disease control rate; DoR, median duration of response; TTR, time to response; TEAEs, treatment-emergent adverse events; irAEs, immune-related adverse events; CI, confidence interval; OR, complete response; PD, progressive disease; PR, partial response; IHC, immunohistochemistry; CPS, combined positive score.

Acknowledgements

- All authors declare no conflict of interest. The authors would like to thank all the patients and their families participating in the trial.
- This study is supported by Shanghai Junshi Biosciences.

2024 ASCO Annual Meeting May 31- June 4, McCormick Place Chicago

At the ASCO Annual Meeting 2024, the preliminary results of the Phase I/II clinical study of tifcemalimab combined with toripalimab and chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC) were first presented in the form of a poster (Abstract No: #8089). The study was a multi-cohort, open-label, multi-center Phase Ib/II clinical study (NCT05664971) led by Professor Lu Shun from Shanghai Chest Hospital, aiming to evaluate the safety and efficacy of tifcemalimab combined with toripalimab and chemotherapy for the first-line treatment in advanced lung cancer patients. Preliminary data show that good anti-tumor effects can be achieved on ES-SCLC patients who have not previously received systemic anti-tumor therapy and received 4 cycles of tifcemalimab (200mg, Q3W) combined with toripalimab (240mg, Q3W) and standard chemotherapy (etoposide + carboplatin/cisplatin), followed by continued maintenance therapy with tifcemalimab combined with toripalimab: 1) Among 43 evaluable patients, the ORR of the first-line treatment with tifcemalimab combined with toripalimab and chemotherapy reached 86.0%, the DCR was 100%, and the median DoR was 4.3 months, PFS was 5.4 months, and the median OS has not yet been reached; 2) the safety is manageable: 97.7% of patients experienced treatment-emergent adverse events (TEAEs) with the incidence of ≥3 grade TEAEs being 88.6%. The incidence of immune-related adverse events (irAEs) was 29.5%. The combination of tifcemalimab with toripalimab and chemotherapy for the first-line treatment of ES-SCLC showed encouraging clinical remission rates, with a manageable safety profile. The study will further evaluate patient survival benefits and long-term safety.

Protection of Intellectual Property Rights

The Company attaches great importance to IP protection and takes various measures to safeguard R&D achievements and technical patents, promoting technological accumulation and product upgrades. The Company has formulated the *Patent Management System* and the *Intangible Assets Management System* in accordance with the *Patent Law*, the *Trademark Law of the People's Republic of China*, the *Patent Examination Guidelines* and other applicable laws and regulations, to standardize intellectual property management, establish mechanisms for maintaining patents, trademarks, and other intangible assets, and fully protect the intellectual property rights of the Company and its partners in fields such as clinical indications and combination therapies.

The Company has set up the Legal and Intellectual Property Department responsible for intellectual property strategy planning, risk management, patent layout and applications, as well as related litigation handling. In terms of trademark management, the Company takes the initiative to apply for trademarks and monitor market usage, with specialized personnel responsible for infringement monitoring and renewal management. For confidentiality management, the Company requires core employees to sign confidentiality agreements upon hiring, and R&D personnel who have access to technical information are also required to sign technical confidentiality agreements to ensure the security of technical information.

Technology Ethics

The Company strictly adheres to industry standards and conducts preclinical pharmacology and toxicology studies at professionally qualified experimental institutions. All research protocols are submitted to the Ethics Committee for rigorous review before implementation. The experiments are conducted by qualified professionals and are fully supervised by the Ethics Committee throughout the process.

In experimental design, the Company scientifically sets up experimental groups and the number of animals, which not only meets the minimum quantity standards required by the guidelines, but also fully complies with the 3R principles of “Reduction, Replacement, and Refinement”, to ensure the scientific validity and reliability of the research while maximizing animal welfare.

- **Reduction**
- **Replacement**
- **Refinement**

Industry Exchanges

The Company actively participates in industry exchanges. In 2024, the Company continued to share its research progress with the industry. A number of research results were published in authoritative international academic journals and international academic conferences, and more doctors and patients were enabled to gain an in-depth understanding of the Company's products through academic meetings and academic and professional exchanges.

The academic meetings the Company participates in are diverse in form, including online meetings that break geographical barriers, offline meetings that promote face-to-face in-depth communication, and online and offline fusion meetings that offer both convenience and interactivity. With varying scale, these academic meetings cover large national summits, provincial exchange forums, and city-level small seminars, fully covering different levels of medical academic exchange scenarios.

Experts Gathered at the Special Meeting of Junshi Biosciences to Discuss New Hope in Tumor Immunotherapy

In September 2024, the “CSCO and I” Special Session of Junshi Biosciences, themed “Wisdom of Experts Enabling Improvement in Every Way”, was cohosted by the Chinese Society of Clinical Oncology (CSCO) and the Company in Xiamen. The session brought together many well-known experts in the field of oncology treatment in China to share research results and clinical experiences in tumor immunotherapy.

The experts presented at the meeting highly praised the research achievements of toripalimab and stated that toripalimab has brought new hope to cancer patients and demonstrated the strength and responsibility of domestic innovative drug. They expressed optimism for future development and hope it will benefit global patients soon.

Meeting Site

Roundtable Discussion

03

Green Operations

Junshi Biosciences views environmental protection as an important cornerstone of sustainable development and is committed to building a comprehensive environmental management system by optimizing resource and energy use, increasing the proportion of clean energy, and reducing energy consumption and carbon emissions. In waste and emission management, the Company implements strict classification and compliant emissions to minimize the impact on the environment, actively responds to climate change, sets greenhouse gas reduction goals, and promotes green and low-carbon transition, contributing to the protection of the ecological environment.

Environmental Management

Key Performance

Annual Total Investment in Environmental Protection
423.55 In 10,000 yuan

Number of Environmental Protection Trainings in 2024
11 Times

Number of Violations of Environmental Laws and Regulations
0 Cases

Amount of Major Administrative Penalties Imposed by Environmental Authorities During the Reporting Period
0 In 10,000 yuan

The Company deeply understands the close connection between corporate development and the ecological environment. In every aspect of daily production and operations, the Company adheres to the resource use policy of "resource conservation, pollution control, compliance with laws, continuous improvement, and green development", and builds and implements a scientifically effective environmental protection management system. The Company has formulated the *Environmental Management Manual*, the *Pollutant Prevention and Discharge Management System*, the *Solid Waste Management System*, the *Environmental Self-Monitoring Management System*, and the *Hidden Environmental Risk Identification and Rectification System*, etc. In addition, the Company, in light of its own development and industry trends, has added the *EHS Management Guidelines for Holding Companies of Junshi Biosciences*, to strengthen the institutional foundation for sustainable development.

The Company identifies and compiles a list of important environmental factors to provide clear guidelines for environmental management; establishes a regular inspection mechanism, which mainly inspects the waste gas treatment and waste water collection and treatment facilities, and rectifies any hidden dangers in a timely manner, so as to ensure the stable operation of the facilities, and formulates a perfect emergency plan for hazardous chemical leakage/hazardous waste leakage and organizes emergency drills, so as to effectively enhance the capability of responding to environmental emergencies.

Emergency Drills for Hazardous Waste Leakage

In October 2024, the Company organized an emergency drill for hazardous waste leakage, aimed at enhancing its ability to respond to environmental emergencies and strengthen the environmental safety and security. The drill simulated an incident where a laboratory technician responsible for waste liquid disposal accidentally fell while transferring waste liquid from the laboratory and caused the spillage of the waste liquid barrel. The drill covered multiple key processes, including emergency plan activation, emergency rescue operations, spill cleanup and disposal, as well as environmental indicator monitoring. It effectively tested and improved the Company's ability to respond to environmental emergencies.


Simulation of Waste Liquid Leakage


Treatment of Waste Liquid Leakage

The Suzhou Wujiang Production Base has obtained the ISO14001 certification, and during the Reporting Period, it successfully completed the audit for ISO14001 certification successfully. The Company set and completed the preset environmental goals such as environmental acceptance upon project completion, compliant hazardous waste disposal, and annual testing for wastewater, exhaust gases or solid waste emissions, and eliminated all major environmental incidents, continuously contributing to green development.


ProCision
环境管理体系认证证书
本证书证明
苏州众合生物医药科技有限公司
管理体系符合
GB/T24001-2016/ISO14001:2015
认 证 范 围
PROCISION

Environmental Management System Certification Certificate of Suzhou Wujiang Production Base

Usage of Resources and Energy

The Company strictly adheres to laws and regulations such as the *Energy Conservation Law of the People's Republic of China*, the *Circular Economy Promotion Law of the People's Republic of China*, the *Law of the People's Republic of China on Clean Production Promotion*, the *Advanced Level, Energy-Saving Level and Access Level of Energy Efficiency of Key Energy-Using Products and Equipment* and the *Measures for the Administration of Carbon Inclusion in Shanghai (Trial)*, and has also established the resource and energy use policy of "resource conservation, pollution control, compliance with laws, continuous improvement, and green development".

Key Performance

Total Water Consumption

416,929 ton

Water Resource Usage Intensity

213.99

ton/RMB 1,000,000 revenue

Comprehensive Energy Consumption

9,702.17 tce

Energy Usage Intensity

4.98 tce/RMB 1,000,000 revenue

Direct Energy Consumption

4,999.50 tce

Including: Gasoline

107.25 ton

Including: Diesel

951.93 Liters

Including: Natural Gas

3,639,460 m^3

Indirect Energy Consumption

4,702.67 tce

Including: Electric Power

38,264.20 MWh

Consumption of Packaging Materials

28.94 ton

Water Resource and Energy Management

The Company is committed to building a resource-saving enterprise. Although the business locations are not in water-scarce areas, the Company actively promotes each operating unit to improve water efficiency and build itself a resource-saving enterprise. We have set clear goals for water resource and energy use, specifically to actively respond to the national “3060” goals (carbon peaking by 2030, carbon neutrality by 2060). With the data support from the energy management system and the effectiveness of energy-saving and emission-reduction measures, the Company further reduces energy consumption in production equipment and improves water resource usage efficiency. During the Reporting Period, the Company continued to implement the following measures to ensure the effective implementation of the goals:

- Establish a water usage record system to monitor and record water consumption during the production process;
- Install some secondary and tertiary water meters to classify and statistically analyze electricity and water consumption more accurately, based on the installed Building Management System (BMS) and energy management system.
- Regularly inspect and maintain the water supply system, increase inspection frequency, strengthen leak point detection and repair, and post water-saving slogans to reduce unnecessary water and energy losses;
- Continue to promote the reclaimed water reuse project, and use reclaimed water for company landscaping and toilet flushing;
- Respond positively to the demand of the power system, adjust electricity usage behavior and patterns as required, avoid peak electricity use, try to avoid using electricity at peak hours and implement economic electricity consumption methods;
- Regularly maintain production equipment, and replace parts in a timely manner when needed, to ensure production efficiency and safety.

The production bases of the Company actively implement energy management. The Suzhou Wujiang Production Base analyzes and controls energy consumption on a quarterly basis from a cost perspective, aiming to minimize energy consumption wherever possible. The Shanghai Lingang Production Base has vigorously carried out equipment renovation, and completed a project of replacing the boiler system with a steam pipeline network, effectively improving energy utilization efficiency. Additionally, a steam condensate water reuse project has been implemented to recover thermal energy, with the reclaimed water used for the cooling tower. The Shanghai Lingang Production Base installed photovoltaic solar equipment on the roof, which is planned to be put into use in 2025, to further explore the path of clean energy utilization, and promote green development.





Raw Materials and Packaging Materials

Junshi Biosciences integrates sustainable development concepts throughout the product packaging management process. Starting from raw materials, the Company selects renewable and environmentally friendly materials to create green package for the products. The design follows the low-carbon philosophy in the principles of simplicity and efficiency to cut down unnecessary resource consumption. The Company cooperates with package material suppliers with industry-recognized green qualifications to ensure that every step of the process meets environmental standards. After the completion of packaging, the Company carries out material balance calculations for all packaging materials and carefully records quantities, so as to promptly discover and solve potential waste problems and realize the comprehensive green transition of the packaging process.

Green Office

In daily operations and management, the Company actively practices the philosophy of green development and advocates the green office mode. It also advocates the recycling of office supplies, to extend the service life of items and reduce the waste of resources.

The Company strengthens employees' awareness of conservation by means such as posting slogans and issuing notices. For example, it actively advocates double-sided printing to reduce paper consumption; encourages employees to save electricity and develop the good habit of turning off lights and setting air-conditioning temperatures reasonably; promotes the recycling of used paper to realize the secondary value of resources; and reasonably plans the driving routes of official vehicles to reduce fuel consumption and carbon emissions. Through these measures, we create a positive atmosphere for everyone to participate in green office practices.

Emission Management

Junshi Biosciences has always attached great importance to waste emission and management, and set up specialized environmental protection, safety and occupational health departments, and assigned EHS professionals with rich experience to handle the related work and effectively manage emissions during research, development, and production processes. In accordance with laws and regulations such as the *Environmental Protection Law of the People's Republic of China*, the *Law of the People's Republic of China on the Prevention and Control of Atmospheric Pollution*, the *Law of the People's Republic of China on Prevention and Control of Environmental Pollution by Solid Wastes*, the Company has formulated internal management systems such as the *General Waste Management System*, the *Solid Waste Management System*, and the *Standard Operating Procedures for Waste Management*, to clarify the requirements for the collection, storage, deactivation, and disposal of various wastes and achieve resource recycling and harmless treatment of waste, thus minimizing the environmental impact of the Company. In addition, we also entrust qualified third-party testing agencies to monitor the Company's wastewater, exhaust gas, plant boundary noise, etc., to ensure that all indicators meet emission standards.

Key Performance

Total waste gas emissions
0.43 ton

Nitrogen oxides (NO_x) emissions
0.3 ton

Sulfur oxides (SO_x) emissions
0.033 ton

Volatile organic compounds (VOCs) emissions
0.09 ton

Particulate matter (PM) emissions
0.009 ton

Total wastewater discharges
122,714 ton

Chemical oxygen demand (COD)
4.53 ton

Ammonia nitrogen
0.3092 ton



Total general waste
163.74 ton

General waste density
0.0840 ton/RMB 1,000,000 revenue

Total dangerous waste
169.31 ton

Dangerous waste density
0.0869 ton/RMB 1,000,000 revenue

Waste Gases

In the research and production process, the Company mainly generates organic exhaust gases, biological aerosols from microbiological experiments, exhaust gases from buffer solution preparation, and exhaust gases from boiler combustion, etc.

To effectively control exhaust gas concentration and reduce environmental pollution, the Company adopts different treatment methods for different types of exhaust gases to ensure that they are properly treated before emission. For example, acidic chemicals used in the preparation of the buffer solution are neutralized through alkaline solution washing and filtration in the spray tower before discharge; organic exhaust gases generated during experiments are collected using fume hoods and regional exhaust systems, and then introduced into an activated carbon adsorption system. After that, they are uniformly discharged through pipes to the exhaust stack. Biological aerosols are filtered through the HEPA filter in the safety cabinet assembly to filter out bacteria and particles therein and realizing the internal circulation. Filters are replaced on a regular basis to guarantee the filtration effect. The Company also strengthens laboratory ventilation to further reduce the risk posed by biological aerosols.

During the Reporting Period, the Company practically fulfilled the responsibility in environmental protection by strictly controlling exhaust gas treatment, ensuring all exhaust gases were properly treated before emission, preventing any incidents of excess exhaust gas emissions, and keeping exhaust gas emission data far below the maximum allowable concentration and emission rate limits stipulated by applicable standards. Our goal for future emissions is to continue to optimize our processes, maintain our current good emissions performance, and tightly control our emissions data to be well below the requirements of applicable standards in the locations where we operate.

Wastewater

The wastewater of the Company mainly includes wastewater generated from the laboratory, wastewater generated from the quality inspection room, biofilter wastewater, inspection wastewater, etc. The concentration of these wastewater discharges meets the indirect discharge limits for biomedical research and development institutions stated in the *Discharge Standard of Pollutants for the Bio-Pharmaceutical Industry (DB31/373-2010)* and the discharge limits of the second category of pollutants stated in the *Shanghai Integrated Wastewater Discharge Standard (DB31/199-2018)*.

Laboratories produce a variety of wastewater types, including cleaning wastewater, sterilizer wastewater, water purifier preparation tailwater, and employee domestic wastewater. After being collected, the wastewater is discharged into the municipal sewage system and ultimately transported to the sewage treatment plant for centralized processing, to ensure compliance with discharge standards. Wastewater generated during the production process, such as that from the quality control room and biological filtration system, is first collected into the Company's self-built wastewater treatment equipment, where wastewater receives pre-treatment to ensure that the treated wastewater meets the required water quality and volume standards for compliant discharge.

Solid Waste

The Company's solid waste is primarily generated from the production process and categorized into general waste and dangerous waste. General waste contains activated sludge, inorganic waste, waste molecular sieves, waste plastics, waste glass, domestic waste, etc. Dangerous waste includes chemical waste liquids, end-of-life pharmaceuticals, waste activated carbon, waste disposable shaker bottles, waste disposable reactors, waste filters, waste ion exchange resins, waste packaging, nonconforming products, and solid wastes from laboratories.

In terms of solid waste treatment, the Company adopts targeted disposal measures for different types of waste. For general solid waste, the Company entrusts qualified third-party disposal companies to ensure compliant treatment, with relevant processes standardized and safe. For dangerous waste, the Company has formulated the *Environmental Risk Assessment Report, the Emergency Response Plan for Environmental Emergencies, the Emergency Plan for Dangerous Waste/Dangerous Chemical Leakage, the Solid Waste Management System* and other guides, to strengthen the safety and protection awareness of personnel involved in dangerous waste/ chemical-related processes, safeguard the safety of the employees and the safety of the working environment, and improve the professional skills and emergency handling capabilities of relevant personnel. The Company collects dangerous wastes generated from the production system and quality control workshops centrally, places them in dedicated sterilization bags, then sterilizes them using high-temperature solid waste sterilization equipment, and stores them in a dangerous waste temporary storage area. After that, professional units with dangerous waste operation licenses are commissioned to receive and treat the waste at fixed times.

In order to protect the safety of employees, the Company requires employees to take necessary protective measures when sorting and transferring dangerous wastes to effectively prevent infection from exposure to dangerous substances. The Company attaches great importance to the management of dangerous waste during the production and experimental processes. In the laboratory and production workshops, designated waste bins for sterilization are placed, and specialized waste liquid collection bins are set up according to the different chemical properties of the experimental waste liquids. The Company places waste liquid bins at fixed locations and posts clear and eye-catching hazard labels, assigns special people to wear protective equipment and transfers dangerous waste at regular intervals. Dangerous waste storage rooms are always well ventilated and environmentally clean, and are managed in a categorized manner to minimize the risk of secondary pollution during storage and transportation.

During the Reporting Period, the Shanghai Lingang Production Base set the target of reducing the intensity of waste generation by 5%, and successfully achieved the target by taking measures such as source control and enhanced management; the Suzhou Wujiang Production Base established control requirements for wastewater discharge to meet relevant standards, exhaust gas emissions to comply with the *Integrated Emission Standard of Air Pollutants*, and 100% legal disposal of dangerous waste, and eventually achieved the full compliance in the discharge of wastewater, waste gases and dangerous waste through management programs such as publicizing relevant regulations, strengthening the operation and maintenance of equipment, enhancing the management of disorganized emission sources, conducting regular inspections, and outsourcing monitoring on a regular basis. In the future, the Company's goal is to further explore sustainable waste recycling and treatment methods, to ensure that all dangerous waste is centrally treated by qualified third-party professional treatment organizations to prevent environmental pollution incidents.

Response to Climate Change

During the critical period when the world is actively responding to climate change and China is vigorously promoting the “carbon peaking and carbon neutrality” strategy, the Company actively responds to the national “carbon peaking and carbon neutrality” goals and actively responds to environmental issues such as climate change. At office locations and production bases, the Company advocates energy conservation and emission reduction, purchases clean energy, improves energy efficiency, and reduces greenhouse gas emissions. During the Reporting Period, the Company carried out greenhouse gas statistics and carbon verification work in a well-organized manner.

Scope 1

5,307.75

tCO_2e

Scope 2

21,493

tCO_2e

Total GHG Emission

26,800.75

tCO_2e



04

Corporate Social Responsibility

Adhering to the corporate spirit of “honorable people are not ostentatious; people of moral integrity are realistic”, Junshi Biosciences integrates pragmatism and responsibility into the core of corporate culture, pays active attention to the career development of employees, helps employees realize their self-worth and growth, and actively fulfills its social responsibility and contributes to the sustainable development of the society.

Caring for Employees

Employment

Compliant Employment

In the principle of compliant employment and in strict compliance with laws and regulations such as the *Labor Law of the People's Republic of China* and the *Labor Contract Law of the People's Republic of China*, the Company has formulated and implemented the *Recruitment Management System of Junshi Biosciences Group* in this year. By standardizing the employment process, the Company effectively protects the legitimate rights and interests of workers, and resolutely eliminates the use of child labor and forced labor and other illegal and unlawful behaviors. Attaching great importance to the diversity of talents, the Company is committed to providing equal opportunities, creating a harmonious and inclusive work environment, and firmly opposing all forms of discrimination. During the Reporting Period, no cases of child labor or forced labor occurred in the Company.

Employee Structure

Total Number of Employees: 2,578 persons

- Number of Female Employees: 1,350 persons
- Number of Male Employees: 1,228 persons

By Employment Type

- Number of Employees under Labor Contracts: 2,566 persons
- Number of Employees under Labor Dispatch Contracts: 0 persons
- Others: 12 persons

By Age

- Number of Employees Aged 30 and below: 777 persons
- Number of Employees Aged 31 to 49: 1,718 persons
- Number of Employees Aged 50 and above: 83 persons

By Work Location

- Employees Working in the Chinese Mainland: 2,548 persons
- Employees Working in Hong Kong, Macau, and Taiwan: 1 persons
- Employees Working in other countries: 29 persons

Number of Ethnic Minority Employees

71 persons

Employee Turnover Rate

19.66%

Honored with 2024 Outstanding Employer Brand

On-campus Recruitment

In 2024, Junshi Biosciences conducted campus recruitment in several well-known universities in China, including Peking University, Tsinghua University, Fudan University, Shanghai Jiao Tong University, China Pharmaceutical University, Xi'an Jiaotong University, and Soochow University. The open positions covered various business segments, and we received 645 students in offline presentations and received 7,287 online resumes.

Campus Recruitment Poster

Campus Recruitment Site

Compensation System

The Company adheres to the principle of equal pay for equal work and is committed to building a fair and transparent compensation system. The Company is performance-oriented and has established a diversified incentive mechanism, which includes year-end bonuses, performance bonuses, and share incentive plans, aiming to fully stimulate employees' potential and achieve deep integration of employees' career development and the Company's strategic goals.

Health and Safety

The Company attaches great importance to employees' occupational health and safety, and has developed and improved safety production management systems to clearly define the responsibilities of each department, in compliance with laws and regulations such as the Law of the People's Republic of China on Work Safety, and the Law of the People's Republic of China on Prevention and Control of Occupational Diseases. The Company provides annual health checkups for employees, arranges occupational disease checkups for laboratory personnel, and pays medical and accident insurance. In addition, we also offer various safety trainings, such as fire drills and chemical leak emergency drills, to enhance employees' safety awareness and emergency response capabilities.

During the Reporting Period, the Company achieved:

100%
coverage of occupational health checkups

100%
coverage of safety production training

0
work-related deaths

49
days lost due to work injury

No safety production accidents with injuries, no environmental pollution exceeding limits, no fire inspection violations and reaching the EHS management goals

Talent Development

The Company attaches great importance to talent training and development, and actively builds a diversified professional talent system to promote the common growth of talent and organization. The Company has built a comprehensive job grading system, providing employees with clear and reasonable career advancement paths and development platforms to meet the Company's needs across its entire industry chain.

In 2024, the Company formulated and implemented the *Employee Training System of Junshi Biosciences Group* to standardize employee training, integrate high-quality internal and external learning resources, enrich training methods, continuously build a learning organization, and strengthen employees' overall capabilities. The Company values future talent reserves. As an off-campus base for professional master's students from China Pharmaceutical University, the Company currently has 12 professional master's students completing their master's thesis work at the off-campus base.

Quality Culture Training

Lingang Public System Technology and Knowledge Sharing Training

Employees' Rights and Interests

Democratic Governance

The Company fully guarantees the employees' rights to know, participate, express and supervise, and insists on improving the employee congress system to ensure the decision-making of the Company is democratic and scientific. The Company has established a diversified employee feedback mechanism, to widely collect employees' opinions and suggestions. Through the disclosure of factory affairs and other ways, we promptly disclose significant corporate decisions and production operations to employees to further enhance the transparency of corporate management.

2024 Employee Congress

Employee Benefits

The Company always prioritizes the well-being of employees, and creates a comprehensive and humane welfare system. In addition to the five social insurances and one housing fund, the Company provides transportation subsidies, meal allowances, holiday benefits, and other thoughtful benefits. For employees in difficulty, the Company has set up a special fund to provide financial assistance and psychological support. Regarding the care for female employees, the Company makes efforts to support the career development and health of female employees, and offers benefits such as pregnancy care, breastfeeding support, regular health lectures and physical checkups, to care for the physical and mental health of female employees.

Employees' Collective Birthday Party

Female Employee Activities

Cultural Activities

The Company adheres to an open, inclusive, and innovative corporate culture, and actively advocates efficient communication and close collaboration among employees. Through regularly holding activities such as corporate culture months and team-building events, the Company helps employees achieve a balance between work and life, improve physical and mental well-being, and further enhance employees' sense of belonging and cohesion.

Group Culture Month: Visit to Wujiang Production Base

Outdoor Activities of Employees

Social Welfare

Charitable Donations

The Company firmly believes that engaging in public welfare activities is both a fulfillment of social responsibility and a key to shape a good corporate image and to enhance employees' sense of pride. With its ongoing development, the Company's commitment to public welfare has grown increasingly resolute.



Online Consultation on World Lung Cancer Day

In November 2024, the Lung Cancer Awareness Month, the Company and Dongdong Oncology provided online free consultation, bringing care and hope to lung cancer patients and their families. Focusing on the two major fields, i.e., non-small-cell lung cancer and small-cell lung cancer, the event launched four live streaming and successfully invited 30 authoritative lung cancer experts from top-tier hospitals across the country to “gather” online. During the live streaming, experts analyzed cases and answered questions for nearly 100 lung cancer patients, with a cumulative viewership of 156,815. This free online consultation not only provided highly professional treatment advice but also spread valuable knowledge about lung cancer, earning widespread recognition and consistent praise from patients.

Support for Upgrades of Primary-Level Healthcare Facilities

The Company has always practiced social responsibility, actively responded to national policies, helped enhance the capacity of county medical resources, and set up an industry benchmark for promoting the balanced development of urban and rural medical resources. The Company donated RMB 0.3 million to the Red Cross Society of Fuping County, Shaanxi Province, to support the local medical emergency system, which involves purchasing automated external defibrillators (AEDs) and ambulances, further popularizing emergency facilities and improving emergency medical capabilities in primary-level healthcare facilities. While focusing on drug research and innovation, the Company continuously gives back to society. We actively participate in building the public healthcare service system, advance the medical and health industry to higher levels, and contribute to the health of the general public, by providing health science education, supporting emergency service of primary-level healthcare facilities, etc.

Representatives of Both Parties Signing the Donation Agreement



Beneficial Healthcare

On the path of promoting medical progress and fulfilling social responsibility, the Company has always adhered to the mission of improving medical accessibility and actively engaging in the practice of beneficial healthcare. The Company believes that high-quality medical resources should not be limited, and that enabling more patients to benefit from cutting-edge medical advancements is an important responsibility for enterprises. Based on this, the Company contributes to the realization of healthcare equity and accessibility through practical actions.

Approved New Indications of Toripalimab

In 2024, the application for new indications of toripalimab, the core product of the Company, i.e., the first-line treatment of advanced triple-negative breast cancer, the first-line treatment of advanced renal cell carcinoma, and the first-line treatment of extensive-stage small-cell lung cancer, was approved by the NMPA. As of the end of the Reporting Period, it had been approved for 10 indications in China and included in the latest version of the National Reimbursement Drug List (NRDL), further expanding the range of benefiting patients with various types of tumors and reducing the medical burden for patients and their families.

The Company continues to expand its global commercialization network. As of the end of the Reporting Period, toripalimab has been approved for marketing in the Chinese Mainland, Hong Kong SAR of China,, the United States, the European Union, India, the United Kingdom, Jordan, and other countries and regions, filling clinical gaps in these areas. In addition, with evidence-based high-quality in treatment of nasopharyngeal cancer, head cancer, neck cancer, lung cancer, breast cancer, esophageal cancer, liver cancer, renal carcinoma, uroepithelial cancer and melanoma, toripalimab has been recommended and recognized by over ten definitive guidelines both domestically and internationally, and has won a number of top-ranking recommendations.

Annex

Key Performance Indicators

Governance

Indicator	Unit	Data for 2024
Number of All Members of the Board of Directors	Persons	14
Including: Number of Female Directors	Persons	4
Including: Number of Executive Directors	Persons	8
Including: Number of Independent Directors	Persons	5
Number of Meetings of Board of Directors	Times	13
Number of Meetings of the Audit Committee	Times	5
Number of Meetings of the Nomination Committee	Times	5
Number of Meetings of the Strategic Committee	Times	1
Number of Meetings of the Remuneration and Appraisal Committee	Times	6
Average Attendance Rate at Meetings of the Board of Directors	%	100
Number of Meetings of the Board of Supervisors	Times	7
Number of the General Meeting of Shareholders	Times	4
Number of Directors Covered by Anti-bribery and Anti-corruption Training	Persons	14
Percentage of Directors Covered by Anti-bribery and Anti-corruption Training	%	100
Number of Senior Management Covered by Anti-bribery and Anti-corruption Training	Persons	7
Percentage of Senior Management Covered by Anti-bribery and Anti-corruption Training	%	100
Number of Employees Covered by Anti-bribery and Anti-corruption Training	Persons	2,578
Percentage of Employees Covered by Anti-bribery and Anti-corruption Training	%	100

Note: The number of personnel involved in above table are the total number of directors, senior management and employees on job as of the end of the reporting period.

Environmental

Indicator	Unit	Data for 2024
Annual Total Investment in Environmental Protection	RMB 10,000	423.55
Number of Environmental Protection Trainings in the Year	Times	11
Number of Violations of Environmental Laws and Regulations	Cases	0
Amount of Major Administrative Penalties Imposed by Environmental Authorities During the Reporting Period	RMB 10,000	0
Comprehensive Energy Consumption	tce	9,702.17

Indicator	Unit	Data for 2024
Energy Usage Intensity	tce/RMB 1,000,000 revenue	4.98
Direct Energy Consumption	tce	4,999.50
Including: Gasoline	ton	107.25
Including: Giesel	Liters	951.93
Including: Natural Gas	m^3	3,639,460
Indirect Energy Consumption	tce	4,702.67
Including: Electricity	MWh	38,264.20
Total GHG Emissions	tCO_2e	26,800.75
Including: Scope 1 GHG Emissions	tCO_2e	5,307.75
Including: Scope 2 GHG Emissions	tCO_2e	21,493
Total waste gas Emissions	ton	0.43
Nitrogen Oxides (NOx) Emissions	ton	0.30
Sulfur Oxides (SOx) Emissions	ton	0.033
Volatile Organic Compounds (VOCs) Emissions	ton	0.09
Particulate Matter (PM) Emissions	ton	0.009
Total Wastewater Discharges	ton	122,714
Chemical Oxygen Demand (COD)	ton	4.53
Ammonia Nitrogen	ton	0.3092
Total Water Consumption	ton	416,929
Water Resource Usage Intensity	ton/ RMB 1,000,000 revenue	213.99
Total general Waste	ton	163.74
General Waste Density	ton/ RMB 1,000,000 revenue	0.0840
Total dangerous Waste	ton	169.31
Dangerous Waste Density	ton/ RMB 1,000,000 revenue	0.0869
Consumption of Packaging Materials	ton	28.94

Social

Indicator	Unit	Data for 2024
Product Recall Rate	%	0
Pharmacovigilance Training Coverage Rate	%	100

Indicator	Unit	Data for 2024
Total Number of Participants in Pharmacovigilance Training	Persons	2,743
Number of Confirmed Data Security Incidents	Cases	0
Specific Amount Involved in Data Security Incidents	In 10,000 yuan	0
Number of Confirmed Customer Privacy Breach Incidents	Cases	0
Specific Amount Involved in Customer Privacy Breach Incidents	In 10,000 yuan	0
Number of patents held	Cases	175
Number of invention patents held	Cases	70
Number of new patents added in the year	Cases	32
Number of patents under review	Cases	284
Number of copyrights held	Cases	10
Total Number of Employees	Persons	2,578
Number of Female Employees	Persons	1,350
Number of Male Employees	Persons	1,228
By Employment Type		
Number of Employees under Labor Contracts	Persons	2,566
Number of Employees under Labor Dispatch Contracts	Persons	0
Others	Persons	12

Indicator	Unit	Data for 2024
By Age		
Number of Employees Aged 30 and below	Persons	777
Number of Employees Aged 31 to 49	Persons	1,718
Number of Employees Aged 50 and above	Persons	83
By Work Location		
Employees Working in the Chinese Mainland	Persons	2,548
Employees Working in Hong Kong, Macau, and Taiwan	Persons	1
Employees Working in other countries	Persons	29
Number of Ethnic Minority Employees	Persons	71
Employee Turnover Rate	%	19.66
By Gender		
Male Employee Turnover Rate	%	21.58
Female Employee Turnover Rate	%	17.83
By Age		
Turnover Rate of Employees Aged 30 and below	%	22.30
Turnover Rate of Employees Aged 31 to 49	%	18.85
Turnover Rate of Employees Aged 50 and above	%	9.78

Indicator	Unit	Data for 2024
By Location		
Turnover Rate of Employees Working in the Chinese Mainland	%	19.75
Turnover Rate of Employees Working in Hong Kong, Macau, and Taiwan	%	0
Turnover Rate of Employees Working in other countries	%	12.12
Coverage of Occupational Health Checkups	%	100
Coverage of Safety Production Training	%	100
Safety Production Accident	Cases	0
Work-related Deaths	Persons	0
Days Lost Due to Work Injury	Day	49
Number of Employee Trainings	Sessions	484
Employee Training Coverage	%	100

Indicator	Unit	Data for 2024
Average number of training hours	Hour	60.59
Average Training Hours of Female Employee	Hour	53.01
Average Training Hours of Male Employee	Hour	68.91
Average Training Hours of Senior Management	Hour	22.64
Number of Suppliers	Unit	2,298
Including: Number of Domestic Suppliers	Unit	2,168
Investment in Public Welfare	RMB 10,000	2,330.94
Donation to Medicine Aid	RMB 10,000	1,107.16

Index of HKEX

Mandatory Disclosure Requirements	Content	Chapters
Governance Structure	A statement from the board containing the following elements: (i) a disclosure of the board's oversight of ESG issues; (ii) the board's ESG management approach and strategy, including the process used to evaluate, prioritize and manage material ESG-related issues (including risks to the issuer's businesses); and (iii) how the board reviews progress made against ESG-related goals and targets with an explanation of how they relate to the issuer's businesses.	Board Statement

Aspects, General Disclosures and KPIs	Content	Chapters
A. Environmental		
Aspect A1	**Emissions**	
General Disclosure	relating to air emissions, discharges into water and land, and generation of hazardous and non-hazardous waste: (a) the policies; and (b) Compliance with relevant laws and regulations that have a significant impact on the issuer Note: Air emissions include NO_x, SO_x, and other pollutants regulated under national laws and regulations. Hazardous wastes are those defined by national regulations.	Green Operations - Environmental Management
KPI A1.1	The types of emissions and respective emissions data.	Green Operations - Emission Management
KPI A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	
KPI A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Green Operations - Response to Climate Change
KPI A1.5	Description of emission target(s) set and steps taken to achieve them.	
KPI A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	

Aspects, General Disclosures and KPIs	Content	Chapters
Aspect A2	**Use of Resources**	
General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials. Note: Resources may be used in production, in storage, transportation, in buildings, electronic equipment, etc.	Green Operations - Use of Resources and Energy
KPI A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	
KPI A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	
KPI A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	
KPI A2.14	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	
KPI A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	
Aspect A3	**Environment and Natural Resources**	
General Disclosure	Policies on minimizing the issuer's significant impacts on the environment and natural resources.	Green Operations
KPI A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	
B. Social		
Employment and Labor Practices		
Aspect B1	**Employment**	
General Disclosure	relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare: (a) the policies; and (b) Compliance with relevant laws and regulations that have a significant impact on the issuer	Corporate Social Responsibility - Caring for Employees
KPI B1.1	Total workforce by gender, employment type (for example, full- or part-time), age group and geographical region.	
KPI B1.2	Employee turnover rate by gender, age group and geographical region.	

Aspects, General Disclosures and KPIs	Content	Chapters
Aspect B2	**Health and Safety**	
General Disclosure	relating to providing a safe working environment and protecting employees from occupational hazards: (a) the policies; and (b) Compliance with relevant laws and regulations that have a significant impact on the issuer	Corporate Social Responsibility - Caring for Employees
KPI B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	
KPI B2.2	Lost days due to work-related injury.	
KPI B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	
Aspect B3	**Development and Training**	
General Disclosure	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities. Description of training activities. Note: Training refers to vocational training. It may include internal and external courses paid by the employer.	Corporate Social Responsibility - Caring for Employees
KPI B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	
KPI B3.2	The average training hours completed per employee by gender and employee category.	
Aspect B4	**Labor Standards**	
General Disclosure	relating to preventing child and forced labor: (a) the policies; and (b) Compliance with relevant laws and regulations that have a significant impact on the issuer	Corporate Social Responsibility - Caring for Employees
KPI B4.1	Description of measures to review employment practices to avoid child and forced labor.	
KPI B4.2	Description of steps taken to eliminate such practices when discovered.	

Aspects, General Disclosures and KPIs	Content	Chapters
Operating Practices		
Aspect B5	**Supply Chain Management**	
General Disclosure	Policies on managing environmental and social risks of the supply chain.	Product Research and Development-Product Responsibility
KPI B5.1	Number of Suppliers (by region)	
KPI B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	
KPI B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	
KPI B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored	
Aspect B6	**Product Responsibility**	
General Disclosure	relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress: (a) the policies; and (b) Compliance with relevant laws and regulations that have a significant impact on the issuer	Product Research and Development-Product Responsibility
KPI B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons	
KPI B6.2	Number of products and service related complaints received and how they are dealt with.	
KPI B6.3	Description of practices relating to observing and protecting intellectual property rights	
KPI B6.4	Description of quality assurance process and recall procedures.	
KPI B6.5	Description of consumer data protection and privacy policies, and how they are implemented and monitored.	

Aspects, General Disclosures and KPIs	Content	Chapters
Aspect B7	**Anti-Corruption**	
General Disclosure	relating to bribery, extortion, fraud and money laundering: (a) the policies; and (b) Compliance with relevant laws and regulations that have a significant impact on the issuer	Sound Governance - Business Ethics
KPI B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	
KPI B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	
KPI B7.3	Description of anti-corruption training provided to directors and staff.	
Communities		
Aspect B8	**Community Investment**	
General Disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	Corporate Social Responsibility - Social Welfare
KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labor needs, health, culture, sport).	
KPI B8.2	Resources contributed (e.g. money or time) to the focus area.	

Reader Feedback Form

Reader Feedback Form for 2024 Environmental, Social, and Governance (ESG) Report

Thank you for reading this report. Please give us your valuable feedback or suggestions on this report to help us improve future reports and better meet your reading needs.

1. Which type of stakeholders do you belong to?

☐ Government Agency ☐ Media/Public ☐ Employee
☐ Shareholder ☐ Partner ☐ Customer
☐ Social Organization ☐ Regulatory Agency ☐ Others (please specify)

2. What would you like to learn from this report?

☐ Company profile ☐ Content Related to Financial Performance
☐ Communication with Stakeholders ☐ Safety Production
☐ Partner Information ☐ Employment and Work Environment
☐ Energy Conservation and Emissions Reduction ☐ Public Welfare Donations
☐ Response to Climate Change ☐ Others (please specify)

3. Do you find the content and layout of this report helpful in finding relevant information?

☐ Yes ☐ No

4. What content in this report satisfies you the most?

☐ Junshi Biosciences at a Glance ☐ Sound Governance ☐ Business Ethics
☐ Product Responsibility ☐ Innovation-driven Development
☐ Environmental Management ☐ Resource and Energy Use
☐ Emissions Management ☐ Response to Climate Change
☐ Employee Employment ☐ Health and Safety
☐ Talent Development ☐ Charitable Donations ☐ Beneficial Healthcare

5. What content in this report needs further improvement?

☐ Junshi Biosciences at a Glance ☐ Sound Governance ☐ Business Ethics
☐ Product Responsibility ☐ Innovation-driven Development
☐ Environmental Management ☐ Resource and Energy Use
☐ Emissions Management ☐ Response to Climate Change
☐ Employee Employment ☐ Health and Safety
☐ Talent Development ☐ Charitable Donations ☐ Beneficial Healthcare

6. Any other comments or suggestions regarding this report?

_____

Your Information

Name _____

Company _____

Position _____

Tel. _____

E-mail _____


君实生物
TopAlliance